Diabetic Retinopathy

Ophthalmology·MeSH: Diabetic Retinopathy

Prevalence

2800.0 / 100K

Incidence

350.0 / 100K/yr

12 drugs in development·8 companies·8 clinical trials

Drug Pipeline by Phase

Phase 3(5)

Drug	Company
ABBV-RGX-314	REGENXBIO Inc. (RGNX)
AXPAXLI	OCULAR THERAPEUTIX, INC (OCUL)
m710	MOMENTA PHARMACEUTICALS INC (MNTA)
surabgene lomparvovec (sura-vec	REGENXBIO Inc. (RGNX)
tarcocimab	Kodiak Sciences Inc. (KOD)

Phase 2(1)

Drug	Company
emixustat	KUBOTA PHARMACEUTICAL HOLDINGS CO LTD (ACUC)

Preclinical(1)

Drug	Company
acu-6151	KUBOTA PHARMACEUTICAL HOLDINGS CO LTD (ACUC)

Unknown(1)

Drug	Company
Lipanthyl™	ABBOTT LABORATORIES (ABT)

Phase 2/Phase 3(4)

Drug	Company
artificial tears	AbbVie Inc. (ABBV)
AT-003	Applied Therapeutics, Inc. (APLT)
sham	AbbVie Inc. (ABBV)
Surabgene Lomparvovec	AbbVie Inc. (ABBV)

BioSniper tracks 12 drugs in development for Diabetic Retinopathy across 8 companies.

There are 8 clinical trials targeting Diabetic Retinopathy tracked by BioSniper.

The estimated prevalence of Diabetic Retinopathy is approximately 2800.0 per 100,000 population.

Full trial data, competitive analysis, and AI-powered pipeline tracking.